Caribou Biosciences, Inc. CRBU

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
41/100
Developing

Ranked against 712 peers in Biotechnology

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, … Full CRBU analysis →

Key risks

  • ROIC Below WACC or Peers ROIC at 26.2th percentile suggests inefficient capital deployment.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.33), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
33
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CRBU ranks in Biotechnology

Caribou Biosciences, Inc. ranks #360 of 713 scored companies in Biotechnology by moat score — the top 50%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
356 NextCure, Inc. NXTC 41/100 Developing
357 Revolution Medicines, Inc. RVMD 41/100 Developing
358 Revolution Medicines, Inc. Warr RVMDW 41/100 Developing
359 ABVC Biopharma, Inc. ABVC 41/100 Developing
360 Caribou Biosciences, Inc. CRBU 41/100 Developing
361 Marker Therapeutics, Inc. MRKR 41/100 Developing
362 Rallybio Corporation RLYB 41/100 Developing
363 Upstream Bio, Inc. UPB 41/100 Developing
364 Coherus BioSciences, Inc. CHRS 41/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How CRBU scores on the Corporate Default defenses

Pricing Power

Score 33 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 39 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 47 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 35 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 61 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 31 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CRBU's moat

What is Caribou Biosciences, Inc.'s moat score?

Caribou Biosciences, Inc. (CRBU) scores 41 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #360 of 713 scored companies in Biotechnology, the top 50%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (61/100) and its weakest is Scale & Market Position (31/100).

How does Caribou Biosciences, Inc. compare with other Biotechnology companies?

Caribou Biosciences, Inc. ranks #360 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are ABVC Biopharma, Inc. (ABVC) at 41 just above it and Marker Therapeutics, Inc. (MRKR) at 41 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Caribou Biosciences, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Caribou Biosciences, Inc.?

The Corporate Default template measures 6 defenses, and CRBU scores: Pricing Power (33), Cost Advantage (39), Customer Stickiness (47), Capital Efficiency (35), Resilience (61), Scale & Market Position (31). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000